Sutro Biopharma, Inc (STRO) Long-Term Debt to Capital Ratio

Sutro Biopharma, Inc. - graphic logo of issuer STRO

Sutro Biopharma, Inc. (STRO) combines its own pilot plant with the engagement of external CMOs for large-scale drug production. The monetization of its antibody-conjugate platform through contracts with industry behemoths drives the long-term debt-to-equity dynamics, where the value of 0.00 represents the most recent figure. The humanitarian status of its developments and stable supplies to US clinics create a neutral backdrop for business growth.

Long-Term Debt to Equity: Sutro Biopharma, Inc. (STRO) for 07/04/2022 - 10/29/2026

Analytical breakdowns for Sutro Biopharma, Inc.

- market price and analyst price targets:
Market Price Sutro Biopharma Inc.|STRO - Price Target Chart
- market capitalization details:
Market Capitalization Sutro Biopharma, Inc.|STRO - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Sutro Biopharma|STRO - Company Book Value|Market-to-Book Ratio sutrobio.com|STRO - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Sutro Biopharma, Inc.|STRO - Long-Term Debt to Equity|Current Liabilities to Capital sutrobio.com|STRO - Company Aggregate Debts|Debt to Net Assets Sutro Biopharma, Inc.|STRO - Company Long-Term Liabilities|Short-Term Debt Sutro Biopharma|Intermediate Coverage Ratio sutrobio.com
- company profitability and valuation multiples indicators:
STRO - Net Profit
Summary company analysis:STRO - Sutro Biopharma Inc.
Brand item of Sutro Bio

Sutro Biopharma, Inc. (STRO) develops high-tech biologics subject to patent dispute risks and logistical disruptions. An analysis of the long-term debt-to-equity ratio on GURU.Markets allows for an assessment of the share of loans with maturities exceeding one year within the capital structure. A decrease in this ratio confirms balance sheet cleanup and increased solvency. However, a complete absence of borrowings may limit R&D investments. This serves as a key marker of the business's financial stability amid geopolitical instability.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Pyxis Oncology - Long-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Long-Term Liabilities to Capital|IOBT: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc